Factors Associated with Daptomycin-Induced Eosinophilic Pneumonia

被引:3
|
作者
Ishikawa, Kazuhiro [1 ]
Matsuo, Takahiro [1 ]
Tsuda, Yasumasa [2 ]
Rahman, Mahbubur [3 ]
Uehara, Yuki [1 ,4 ,5 ,6 ]
Mori, Nobuyoshi [1 ]
机构
[1] St Lukes Int Hosp, Dept Infect Dis, Tokyo 1048560, Japan
[2] St Lukes Int Hosp, Dept Pharm, Chuo Ku, Tokyo 1048560, Japan
[3] St Lukes Int Univ, Grad Sch Publ Hlth, Div Epidemiol, Tokyo 1040045, Japan
[4] St Lukes Int Hosp, Dept Clin Lab, Tokyo 1048560, Japan
[5] Juntendo Univ, Fac Med, Dept Microbiol, Tokyo 1138421, Japan
[6] Juntendo Univ, Fac Med, Dept Gen Med, Tokyo 1138421, Japan
来源
ANTIBIOTICS-BASEL | 2022年 / 11卷 / 02期
关键词
daptomycin; eosinophilic pneumonia; Staphylococcus aureus; methicillin-resistant Staphylococcus aureus; HIGH-DOSE DAPTOMYCIN; EPIDEMIOLOGY; INFECTIONS; SAFETY;
D O I
10.3390/antibiotics11020254
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The risk factors for eosinophilic pneumonia (EP) remain unclear. We investigate the characteristics of patients with daptomycin (DAP)-induced EP and conducted a retrospective observational study. A total of 450 patients aged >= 18 years who received DAP (25 DAP with EP, 425 DAP without EP) were included. The median duration from the first DAP administration to EP onset was 18.0 days. Definite, probable, and possible DAP-induced EP were diagnosed in 0, 9, and 16 patients, respectively. The median age (DAP with EP, 72.0 years; DAP without EP, 64.0 years), DAP dosage/body weight (BW) (9.00 vs. 7.50 mg/kg), blood eosinophil count (cells/mu L) (419 vs. 96), and the percentage of hemodialyzed patients (40.0% vs. 13.4%) were significantly higher in patients with EP than in patients without EP in the univariate analysis. In separate multivariate logistic regression analyses, age (odds ratio (OR), 1.03; 95% confidence interval (CI), 1.00-1.05), DAP dosage/BW (OR, 1.61; 95% CI, 1.25-2.07), and hemodialysis (OR, 4.42; 95% CI, 1.86-10.5) were significantly associated with DAP-induced EP. Clinicians may need to consider the potential factors associated with EP, especially in older patients, patients on hemodialysis, or patients who receive > 9.00 mg/kg of DAP.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Daptomycin-Induced Eosinophilic Pneumonia
    Brixey, A. G.
    Willers, E. D.
    Ferrell, P. B.
    Light, R. W.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2011, 183
  • [2] Daptomycin-induced eosinophilic pneumonia
    Roux, Sandrine
    Ferry, Tristan
    Chidiac, Christian
    Valour, Florent
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2015, 37 : 95 - 96
  • [3] Daptomycin-Induced Eosinophilic Pneumonia
    Chan, R.
    Sakhamuri, P.
    Walker, S.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
  • [4] Daptomycin-Induced Eosinophilic Pneumonia
    Riehani, A.
    Cooke, G.
    Stewart, J.
    Sharma, M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [5] Daptomycin-induced eosinophilic pneumonia
    Hassett, Michael R.
    JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS, 2024, 37 (04): : 4 - 4
  • [6] Daptomycin-induced eosinophilic pneumonia: Are there any risk factors?
    Ahouansou, Nelly
    Georges, Marjolaine
    Beltramo, Guillaume
    Aswad, Nicolas
    Hassani, Yasmina
    Bonniaud, Philippe
    INFECTIOUS DISEASES NOW, 2021, 51 (07): : 618 - 621
  • [7] DAPTOMYCIN-INDUCED ACUTE EOSINOPHILIC PNEUMONIA
    Chilingarashvili, Giorgi
    Mohan, Arjunmohan
    Lazar, Roxana
    CHEST, 2024, 166 (04) : 3473A - 3474A
  • [8] THE CASE OF DAPTOMYCIN-INDUCED EOSINOPHILIC PNEUMONIA
    Gerts, Neil
    Nathan, Ramesh
    Takher, Jasprit
    CHEST, 2023, 164 (04) : 3325A - 3326A
  • [9] Daptomycin-Induced Acute Eosinophilic Pneumonia
    Portalatin, Gilda M.
    Chin, Jodi-Ann
    Foster, Brian
    Perry, Kevin
    McWilliams, Carla
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (02)
  • [10] Daptomycin-Induced Acute Eosinophilic Pneumonia
    Hilal, T.
    Khosravi, M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 191